The CJC-1295 + Ipamorelin blend pairs two peptides frequently studied together in growth-hormone-axis research. This guide summarizes what the published scientific literature has examined about each component, their molecular profiles, and how the blend is handled in a research setting. It is written for researchers and is not medical guidance.
What is the CJC-1295 + Ipamorelin blend?
This is a two-component research blend:
- CJC-1295 (without DAC): a synthetic analog of growth-hormone-releasing hormone (GHRH) studied for its activity at the GHRH receptor.
- Ipamorelin (CAS 170851-70-4, molecular formula C38H49N9O5, molar mass ≈ 711.9 g/mol), a selective growth-hormone secretagogue and ghrelin-receptor agonist.
Research-use note: This blend is supplied strictly for laboratory research. It is not an approved drug or supplement and is not for human or animal consumption. Findings below come from published research studies.
Evidence at a glance
Components studied separatelyEach component has its own literature, including early human pharmacokinetic work on CJC-1295. The blend as sold has not been studied as a combination.
Why researchers are interested
The two act on different receptors, GHRH and ghrelin, so they raise growth hormone by separate routes. Pairing complementary mechanisms is the rationale for the blend, and ipamorelin was picked specifically for raising growth hormone without dragging cortisol and prolactin up with it.
What the research found
- Sustained GH and IGF-1 increaseCJC-1295 raised growth hormone several fold and IGF-1 for days after a single dose (Teichman, 2006)
- Selective GH releaseIpamorelin raised growth hormone without the cortisol or prolactin rise seen with earlier secretagogues (Raun, 1998)
- Natural pulsatility retainedBoth act upstream of the pituitary, so release follows the body's own pulse pattern
Reported in the literature
- Injection site reactions and flushing were reported in the early CJC-1295 human study.
- No published trial has studied the two peptides given together, so the combination has no safety data of its own.
- Neither component is approved, and there is no long term human safety data for either.
- Growth hormone secretagogues are prohibited in competitive sport under the WADA Prohibited List.
Findings are summarised from the sources listed under References on this page, and from approved product labelling where a compound has one. These are outcomes observed in published studies, not effects claimed for any person, and nothing here is a recommendation for human use.
How the blend works (the mechanism studied)
The two peptides act on complementary pathways of growth-hormone regulation. CJC-1295 is studied as a GHRH-receptor agonist, while ipamorelin is studied as a selective secretagogue acting at the ghrelin/GH-secretagogue receptor. Researchers have examined each pathway for its influence on growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in study models, which is why the two are commonly combined in research protocols.
What researchers have studied
- CJC-1295: Teichman et al. (J Clin Endocrinol Metab, 2006) examined prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults.
- Ipamorelin: Raun et al. (European Journal of Endocrinology, 1998) characterized ipamorelin as the first selective growth-hormone secretagogue.
These findings belong to the published research record and do not represent approved or validated uses of the research compounds sold here. See also our tesamorelin research guide on a related GHRH analog.
Handling and reconstitution in the laboratory
The blend is typically supplied as a lyophilized powder for research use. Standard laboratory practice is to reconstitute it with bacteriostatic water, swirl (not shake) until dissolved, and store the reconstituted solution refrigerated (2–8 °C). The lyophilized powder is generally stored frozen and protected from light. (General lab-handling notes, not usage instructions.)
For research use only
All products and information referenced here are intended strictly for laboratory and scientific research use only. They are not for human or animal consumption and are not drugs, foods, supplements, or medical devices. No statement here should be interpreted as medical advice.
Explore this blend and related research peptides
- CJC-1295 + Ipamorelin 10mg, verified specifications
- Tesamorelin 10mg, GHRH-analog research peptide
- Bacteriostatic Water 30ml, reconstitution diluent
References
- Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed